✦ LIBER ✦

Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis

✍ Scribed by Baker, Stephen J.; Zhang, Yong-Kang; Akama, Tsutomu; Lau, Agnes; Zhou, Huchen; Hernandez, Vincent; Mao, Weimin; Alley, M. R. K.; Sanders, Virginia; Plattner, Jacob J.

Book ID: 119942197
Publisher: American Chemical Society
Year: 2006
Tongue: English
Weight: 66 KB
Volume: 49
Category: Article
ISSN: 0022-2623
DOI: 10.1021/jm0603724

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Synthesis of isotopically labelled [3-14

Synthesis of isotopically labelled [3-14C]- and [3,3-2H2]-5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), a new antifungal agent for the potential treatment of onychomycosis

✍ Stephen J. Baker; Yong-Kang Zhang; Tsutomu Akama; Conrad Wheeler; Jacob J. Platt 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 113 KB

## Abstract 5‐Fluoro‐1,3‐dihydro‐1‐hydroxy‐2,1‐benzoxaborole (AN2690) is a new antifungal agent for the potential treatment of onychomycosis. During the preclinical development phase, it was necessary to synthesize the radioisotope [3‐^14^C]‐5‐fluoro‐1,3‐dihydro‐1‐hydroxy‐2,1‐benzoxaborole and the

Discovery of N-benzyl-2-[(4S)-4-(1H-indo

Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity

✍ Richard L. Elliott; Kimberly O. Cameron; Janice E. Chin; Jeremy A. Bartlett; Ele 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 598 KB

We describe the design, synthesis, and structure-activity relationships of triazolobenzodiazepinone CCK1 receptor agonists. Analogs in this series demonstrate potent agonist activity as measured by in vitro and in vivo assays for CCK1 agonism. Our efforts resulted in the identification of compound 4

ChemInform Abstract: Discovery of N-Benz

ChemInform Abstract: Discovery of N-Benzyl-2- [(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H- [1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide (I), an Orally Active, Gut-Selective CCK1 Receptor Agonist for the Potential Treatment of Obesity.

✍ Kimberly O. Cameron; et al. et al. 📂 Article 📅 2011 🏛 John Wiley and Sons ⚖ 23 KB 👁 1 views

Discovery of (1R,5S)-N-[3-Amino-1-(cyclo

Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection

✍ Venkatraman, Srikanth; Bogen, Stéphane L.; Arasappan, Ashok; Bennett, Frank; Che 📂 Article 📅 2006 🏛 American Chemical Society 🌐 English ⚖ 312 KB